Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Postmarket Drug Safety Information for Patients and Providers

Postmarket Drug Safety Information for Patients and Providers

                        Index to Drug-Specific Information Home
          Drugs
          Drug Safety and Availability
          Postmarket Drug Safety Information for Patients and Providers
          Relenza (zanamivir) InformationPostmarket Drug Safety Information for Patients and Providers Relenza (zanamivir) Information
  
  	
    Share
    Post
    Linkedin

    Email
    PrintRelenza (zanamivir) is an inhalation powder for oral inhalation approved for treatment of acute uncomplicated illness due to influenza A and B virus in adults and pediatric patients aged 7 years of age and older who have been symptomatic for no more than 2 days.Relenza is indicated for preventive use (prophylaxis) in adults and pediatric patients aged 5 years of age and older.Relenza is not a substitute for early influenza vaccination on an annual basis.*Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.*Related InformationRelenza: Consumer Questions and AnswersRelenza (zanamivir) Inhalation Powder Dear Healthcare Professional Letter - October 2009Historical Information on Relenza (zanamivir)Labeling and Regulatory History from Drugs@FDAPrescribing Information - Relenza (zanamivir) Inhalation Powder for oral inhalationResourcesForYouInfluenza (Flu) Antiviral Drugs and Related Information

                                                                                  Content current as of:
      09/11/2018Postmarket Drug Safety Information for Patients and Providers

          
                        Index to Drug-Specific Information
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop